Adverum Biotechnologies Presents Long-term Data through March 10, 2021 from the OPTIC Trial of ADVM-022 Intravitreal Gene Therapy in Treatment-experienced Wet AMD Patients at ARVO 2021

    NEXT STORY
    EBS EQUITY ALERT: Kessler Topaz Meltzer & Check, LLP Announces that a Securities Fraud Class Action Lawsuit was filed on Behalf of Investors of Emergent BioSolutions Inc.
    PREV STORY
    Novartis Phase III Beovu® data show potential for fluid resolution in more diabetic macular edema patients with fewer injections versus aflibercept
    Subscribe to PM360
    Print Subscription
    Follow Us

    Experts on Call

    Get in touch with PM360 Experts On Call

    Ads

    You May Also Like

    Global Precision Medicine Market 2018-2028 with 2017 as the Base Year – Market to Reach $216.75 Billion

    author_avatar
    NASDAQ Market News

    FDA expedites review of Novartis drug Promacta® for first-line severe aplastic anemia (SAA)

    Promacta receives FDA Priority Review for first-line treatment of SAA based on data showing ...

    author_avatar
    NASDAQ Market News

    Prospective Data Demonstrates Effective Pain Relief and Improved Function Using Medtronic’s Evolve(SM) Workflow with Spinal Cord Stimulation

    author_avatar
    NASDAQ Market News